AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$55.07
neg -0.21
-0.38%
Today's Range: 54.96 - 55.53 | ABBV Avg Daily Volume: 10,343,500
Last Update: 09/02/14 - 4:00 PM EDT
Volume: 7,354,811
YTD Performance: 4.68%
Open: $55.43
Previous Close: $55.28
52 Week Range: $42.30 - $58.27
Oustanding Shares: 1,591,699,124
Market Cap: 87,989,127,575
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 4 4
Moderate Buy 0 0 0 1
Hold 2 2 4 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.57 1.57 2.00 2.05
Latest Dividend: 0.42
Latest Dividend Yield: 3.04%
Dividend Ex-Date: 07/11/14
Price Earnings Ratio: 21.43
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
21.43 12.00 29.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.31% 29.70% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
EBITDA 6.97B
Revenue 18.38B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.77 $0.88 $3.15 $4.02
Number of Analysts 3 2 6 6
High Estimate $0.78 $0.92 $3.23 $4.30
Low Estimate $0.77 $0.83 $3.10 $3.76
Prior Year $0.82 $0.82 $3.14 $3.15
Growth Rate (Year over Year) -5.69% 6.71% 0.37% 27.39%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateAbbVie upgraded at UBS

Jul 28, 2014 | 8:03 AM EDT

ABBV was upgraded to Buy from Neutral, UBS said. Reflective of accretive Shire deal. $67 price target. 

bullishAbbvie added to US 1 List at BofA/Merrill

Jul 23, 2014 | 7:41 AM EDT

ABBV was placed on the US 1 list, according to Bank of America/Merrill Lynch said. Estimates also increased, given higher expected Hepatitis C sales and synergies from the Shire deal. 

By

Doug Kass

 | Jul 14, 2014 | 8:06 AM EDT
Where it began.

bullishAbbvie upgraded at Morgan Stanley

May 7, 2014 | 8:12 AM EDT

ABBV was upgraded from Equal-weight to Overweight, Morgan Stanley said. $60 price target. Company has an attractive pipeline and can generate healthy growth over the coming quarters. 

By

Jim Cramer

 | Apr 30, 2014 | 8:11 AM EDT

The market wants companies that are taking share with minimal spending.

By

Chris Laudani

 | Apr 24, 2014 | 12:00 PM EDT

Investors may be worried about Sovaldi's price.

By

Jim Cramer

 | Apr 23, 2014 | 3:48 PM EDT

Its potent hepatitis C treatment is not a boon for shareholders.

By

Gary Dvorchak

 | Apr 9, 2014 | 12:30 PM EDT

The goal is always simply to get out where we got in.

bearishAbbVie price target lowered at Jefferies

Mar 19, 2014 | 7:33 AM EDT

ABBV cut its number, Jefferies said. Competitive data in Hep C, pay for delay litigation re Androgel. $60 price target. 

bearishAbbvie downgraded at Morgan Stanley

Dec 19, 2013 | 7:48 AM EST

ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $57 price target. 

I'm eyeing possible support in this one....writing about this tonight!

...
It was a quiet start to the week, in as much as the broader market was concerned. With on...
Market closes flat as oil & commodities take hit today on back of stronger dollar...so...
Latest PAYX/IHS Small Business Jobs Index released today...Mountain region and Texas metro...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.